- email:registrations@informa-ls.com
- phone:+44(0)20 7017 7481
18 days to go - register NOW!
6th Annual
Immunogenicity for Biologics
28 - 29 September 2010, Sheraton Brussels Hotel, Belgium
The 6th Annual Immunogenicity for Biologics Conference
Informa’s Immunogenicity provides a comprehensive overview of the latest developments in immunogenicity for biologics.
This year’s event will examine recent advances in technologies for assessing immune responses, as well as the challenges posed by newer therapeutics – from PEGylated biologics to trifunctional antibodies and gene therapy.
Examine the new FDA Immunogenicity guidelines, as well as the implications of new EMA guidelines on monoclonal antibodies.
Evaluate the latest immunoassay platforms, strategies for predicting immunogenicity, prevention of ADA generation and the clinical relevance of immunoassay results. Plus discuss the use of PK/PD data alongside ligand binding and cell based assays in immunogenicity assessment.
Highlights of EU Pharmaceutical Law Forum 2010
- Crucial advice from the National Institute for Biological Standards and Control and the FDA read more
- Understand the true clinical relevance of your results read more
- Explore the cutting edge in immunoassay technologies and assessment of complex therapeutics read more
- Anticipate potential immunogenic triggers and lower the risk of immunogenicity read more
Expert speakers
Expert speakers
Dr Susan Krishner
Lab of Immunology
FDA
|
Dr Deborah Finco
Principal Scientist, Immunotoxicology
Pfizer
|
Professor Annie de Groot
Director, Institute for Immunology
University of Rhode Island
|
Prof Wim Jiskoot
Drug Delivery Technology
University of Leiden
|
Professor Roy Jefferis
Division of Immunity and
Infection University of Birmingham, UK |
Dr Julia Schleypen
Head of Protein Bioanalytics
Roche
|
Dr David Goldsmith
Consultant Nephrologist
Guy’s and St Thomas’ Hospital
|
Dr Michael Tovey
Director of Research
Institute Andre Lwoff
|
..
Spotlight Presentation Sponsor
..
..
..
..
Lanyard Sponsor
..
..
..
..
Exhibitors
..
..
..
Dates and Venues
28 Sep 2010 - 29 Sep 2010
Sheraton Brussels Hotel, Belgium
NEW Workshop leader announced
We are pleased to welcome Dr Martin Schaefer from Roche who will co-present our post-conference workshop:
Practical Advice for Development and Validation of Neutralising Antibody Assays.
Post-Conference workshop: Thursday 30th September
Practical Advice for Development and Validation of Neutralising Antibody Assays
- Risk assessment strategy
- Optimisation & validation of neutralising antibody assays
- Design and development of a cell based Nab assay
- Review of recent FDA guidance on Nab assays
Led by
Dr Hicham Alaoui, Stryker
Dr Martin Schaefer, Roche
Pre-Conference workshop: Monday 27th September
Best Practice in the Detection and Characterisation of Immune Responses to Therapeutics
-
Effective measurement and characterisation of ADAs
-
Best practice in standardisation and validation of assays
-
Correct application of regulatory guidelines
Led by
Dr Nadja Prang, Biochallenges Consulting
Dr Olivia Vetterlein, UCB Celltech
Attendees to date
Nycomed GmbH
Sandoz
Regeneron Pharmaceuticals Inc
Aptuit
CHRU de Tours
Solvay Pharmaceuticals BV
Facet Biotech
Dr Klaus Vosbeck GmbH
CEA Saclay
Johnson Johnson
PharmaNet Inc
Sunstone Capital AS
Schering Plough
Berna Biotech Ltd
Novozymes Biopharma UK Ltd
National Institute for Biological Standards Control
7TM Pharma
Institut Andre Lwoff
Huntingdon Research Centre
Neutec Pharma Ltd
Baxter AG
Dr H J Friesen
Paion Deutschland GmbH
MDS Pharma Services
Icon Development Solutions
Zealand Pharma AS MicroCoat Biotechnologie GmbH
Biocon Ltd
Quotient Bioresearch
Sailstad Associates Inc
Acceleron Pharma
Merck KG
Momenta Pharmaceuticals Inc
Yonsei University Medical Center
MacroGenics Inc
Genmab BV
Phadia GmbH
PRA International
Genzyme Corp
Optherion Inc
BioMonitor AS
Chugai Pharmaceutical Co Ltd
Trion Research
Bioscience Valuation BSV GmbH
Proteus SA
Eurofins Medinet BV
Dr Kamran Salim Cambridge Regulatory Services
Inno Biologics Sdn Bhd
Flamel Technologies
Texcell
Huntingdon Life Sciences
University of Geneva
Generic Pharmaceutical Association
Kenta Biotech AG
Covance Laboratories Ltd
BioReliance
NewLab BioQuality GmbH
NeuroNova AB
Pharma Scientific Services Team
LFB
Sanofi Aventis
Ferring Pharmaceuticals AS
TNO
IP Group
Molecular Partners AG
BSL Bioservice
Noxxon Pharma AG
NDA Regulatory Service
Sanquin
Octagene Biopharmaceuticals GmbH
SeroScience Ltd
Maxygen Inc
Institute de Recherche Pierre Fabre
Micromet AG
ProImmune Inc
SCIL Proteins GmbH
Medac GmbH
Biomedical Diagnostics
AlgoNomics NV
Fraunhofer Institute of Toxicology Experimental Medicine
Guys St Thomas NHS Foundation Trust
Health Protection Agency
Teva Pharmaceutical Industries Ltd
Parexel Intl GmbH
ProBioGen AG
Ranbaxy Labs Ltd
NIBSC-Biotherapeutics
CEVEC Pharmaceuticals GmbH
Richter Plc
Jan van Breemen Instituut
Ablynx
Aptuit Edinburgh Ltd
HGS
Kuros Biosurgery AG
MorphoSys AG
Parexel
BTG - Protherics
BioGeneriX AG
Fresenius Biotech GmbH
Bayer Schering Pharma AG
Biogen Idec
Biotest AG
Charles River Laboratories
ForteBio Inc
Synexel Research Intl
Hogan Hartson LLP
F Hoffmann La Roche
Forschungszentrum Julich GmbH
Jerini AG
GE Healthcare
Novo Nordisk
Axicorp GmbH
SciGen
University of Birmingham
Ipsen Pharma SA
Antitope Ltd
AMT Biopharma BV
UCL
Dait Niaid Nih
Merck Serono SpA
Transgene
Dr Reddys Laboratories Ltd
CIRION
H Lundbeck AS
Instituto Grifols SA
Nordic Bioscience AS
Novartis Pharma AG
BioMarin Pharmaceuticals Inc
Abbott Pharmaceuticals
Decision Resources Inc
Rigshospitalet
OrbusNeich
Talecris Biotherapeutics
Paul Ehrlich Institut
Spotlight Sponsors
Poll
Do you think isotyping of anti-drug antibodies is relevant for safety and efficacy determination?
Please select an answer
Reviews
"This is one of the best conferences I’ve attended. Comprehensive and combining open discussions on scientific, clinical, and industrial issues."
"Interesting, well focused, and a good opportunity to meet and share information with colleagues of other companies."
